Public record
Saxenda: the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Medicaid
Medicaid prescriptions for Saxenda by state
State Medicaid programmes paid for 28,807 Saxenda prescriptions in 2025, with $34.2M reimbursed before rebates. California reported the most (10,868), followed by Virginia (8,783) and Michigan (2,442); 15 states and territories reported any.
| Measure | Value | Note |
|---|---|---|
| Prescriptions paid by Medicaid, 2025 | 28,807 | |
| Total reimbursed before rebates, 2025 | $34.2M | |
| States and territories reporting | 15 | with at least one count CMS did not suppress |
| California | 10,868 prescriptions | $13.2M reimbursed |
| Virginia | 8,783 prescriptions | $10.2M reimbursed |
| Michigan | 2,442 prescriptions | $3.0M reimbursed |
| Minnesota | 2,091 prescriptions | $2.4M reimbursed |
| Pennsylvania | 1,542 prescriptions | $2.0M reimbursed |
How this was calculated
Matched each Medicaid product code to the FDA NDC Directory by labeler and product code, kept finished single-ingredient products, then summed prescriptions and reimbursement by state. National roll-up and suppressed rows dropped.
Saxenda only (brand-name liraglutide), fee-for-service and managed care, 2025
Counts under 11 are suppressed by CMS and left out, so totals are a floor. Amounts are before rebates. Differences between states reflect programme size and coverage rules. Compounded products are not included.
Pharmacy cost
Pharmacy acquisition cost (NADAC) for Saxenda
Retail pharmacies paid an average of $87.04 per mL for SAXENDA 18 MG/3 ML PEN as of 2026-11-11, compared with $86.99 twelve months earlier (+0.1%). This is a pharmacy purchase cost, not a patient price.
| Measure | Value |
|---|---|
| SAXENDA 18 MG/3 ML PEN, now | $87.04 per mL |
| SAXENDA 18 MG/3 ML PEN, 12 months earlier | $86.99 per mL |
| Change over 12 months | +0.1% |
How this was calculated
Matched NADAC product codes to the FDA NDC Directory, kept finished single-ingredient products, and listed the product descriptions with the most package codes. The earlier price is the same package code in the file one year before.
Saxenda (brand-name liraglutide) in the weekly NADAC file of 2026-11-11, compared with the file of 2025-11-12
NADAC is the average invoice price retail pharmacies pay, from a voluntary survey. It leaves out rebates, dispensing fees and markups, and it is not what a patient or insurer pays. Compounded products are not surveyed.
Articles on Saxenda
- Saxenda Cost vs. Alternatives: What You Actually Pay and What You Get
- Saxenda Manufacturer Copay Program: How to Cut Your Out-of-Pocket Cost in 2026
- Saxenda Patient Assistance for Low-Income Patients: How to Get Liraglutide 3 mg at Reduced or Zero Cost
- Does Blue Cross Blue Shield Cover Saxenda?
- Does Blue Cross Blue Shield of Illinois Cover Saxenda?
- Does Blue Cross Blue Shield of North Carolina Cover Saxenda?